Holen Sie sich die Stockscreener-App
2.21
0.90%
-0.0201
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Future Industry Growth Of Cognitive Behavioral Therapy - openPR
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Minerva Neurosciences reports voting results from annual meeting By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.07 - Investing.com India
Minerva Neurosciences stock hits 52-week low at $2.07 By Investing.com - Investing.com UK
Minerva Neurosciences reports voting results from annual meeting - Investing.com
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences : ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class ActionNERV - Marketscreener.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.25% - MSN
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
500: Something went wrong - Investing.com
Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada
Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
Rubertis Francesco De Net Worth (2024) - GuruFocus.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World
HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World
Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online
Roche's Ocrevus Subcutaneous Gets European Commission Nod - Markets Insider
Minerva Neurosciences - The Pharma Letter
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Yahoo Finance
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug - Yahoo Finance
4.33%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):